Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Impact of omeprazole on the plasma clearance of methotrexate.

Literature DB >> 8269594

Impact of omeprazole on the plasma clearance of methotrexate.

T Reid¹, A Yuen, M Catolico, R W Carlson.

Abstract

Omeprazole inhibits the gastric hydrogen pump and is an effective treatment for peptic ulcers. Methotrexate is a chemotherapeutic agent that inhibits dihydrofolate reductase and is eliminated by a hydrogen-ion-dependent mechanism in the kidney. We present evidence that omeprazole inhibits methotrexate clearance and may result in potentially toxic methotrexate levels.

Entities: Chemical Disease

Mesh：

Substances：
Omeprazole
Methotrexate

Year: 1993 PMID： 8269594 DOI： 10.1007/bf00686028

Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333

25 in total

1. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis.

Authors: G F Webster; L K Razsi; M Sanchez; J L Shupack
Journal: J Am Acad Dermatol Date: 1991-03 Impact factor: 11.527

2. Biochemical and functional characterization of H(+)-K(+)-ATPase in distal amphibian nephron.

Authors: G Planelles; T Anagnostopoulos; L Cheval; A Doucet
Journal: Am J Physiol Date: 1991-06

3. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease.

Authors: J L Jorizzo; W L White; C M Wise; M D Zanolli; E F Sherertz
Journal: J Am Acad Dermatol Date: 1991-06 Impact factor: 11.527

4. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors: M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal: N Engl J Med Date: 1986-06-19 Impact factor: 91.245

5. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue.

Authors: W H Isacoff; P F Morrison; J Aroesty; K L Willis; J B Block; T L Lincoln
Journal: Cancer Treat Rep Date: 1977-12

Review 6. High-dose methotrexate: a critical reappraisal.

Authors: S P Ackland; R L Schilsky
Journal: J Clin Oncol Date: 1987-12 Impact factor: 44.544

7. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate.

Authors: M A Antonelli; L W Moreland; J E Brick
Journal: Am J Med Date: 1991-03 Impact factor: 4.965

8. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.

Authors: H T Abelson; M T Fosburg; G P Beardsley; A M Goorin; C Gorka; M Link; D Link
Journal: J Clin Oncol Date: 1983-03 Impact factor: 44.544

Review 9. The pharmacology of methotrexate.

Authors: E A Olsen
Journal: J Am Acad Dermatol Date: 1991-08 Impact factor: 11.527

Review 10. Methotrexate. I. Pharmacology and pharmacokinetics.

Authors: R J Lippens
Journal: Am J Pediatr Hematol Oncol Date: 1984

13 in total

1. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs.

Authors: Marsha L Voll; Kim D Yap; Wim E Terpstra; Mirjam Crul
Journal: Pharm World Sci Date: 2010-07-20

Review 2. Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors: Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal: Drug Saf Date: 2006 Impact factor: 5.606

Review 3. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.

Authors: Shewit Bezabeh; Ann Corken Mackey; Paul Kluetz; Dilara Jappar; Joyce Korvick
Journal: Oncologist Date: 2012-04-03

Review 4. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis.

Authors: Xi Wang; Yanqin Song; Jingjing Wang; Jin He; Ruming Liu; Xiaosu Li; Hua Huang; Jun Zhang
Journal: Int J Clin Pharm Date: 2020-01-08

5. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

Authors: M Joerger; A D R Huitema; H J G D van den Bongard; P Baas; J H Schornagel; J H M Schellens; J H Beijnen
Journal: Br J Clin Pharmacol Date: 2006-07 Impact factor: 4.335

6. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report.

Authors: Tiene G M Bauters; Joris Verlooy; Hugo Robays; Geneviéve Laureys
Journal: Pharm World Sci Date: 2008-04-04

7. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.

Authors: M Joerger; A D R Huitema; S Krähenbühl; J H M Schellens; T Cerny; M Reni; E Zucca; F Cavalli; A J M Ferreri
Journal: Br J Cancer Date: 2010-02-02 Impact factor: 7.640